Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.22.2.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-in- Capital
Treasury Stock
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Total
Beginning balance at Jan. 02, 2021 $ 51 $ 260,260 $ (7,146) $ (215) $ (169,461) $ 83,489
Beginning balance (in shares) at Jan. 02, 2021 48,091          
Increase (Decrease) in Stockholders' Equity            
Net income (loss)         (2,722) (2,722)
Issuance of shares in connection with stock option exercise   163       163
Issuance of shares in connection with stock option exercise (in shares) 130          
Issuance of shares in connection with restricted stock units vesting $ 2 (6)       (4)
Issuance of shares in connection with restricted stock units vesting (in shares) 2,382          
Share-based compensation   4,080       4,080
Issuance of shares in connection with BOD Fees   6       6
Unrealized gain (loss) on deferred compensation trust assets       35   35
Effect of changes in foreign currencies       14   14
Ending balance at Apr. 03, 2021 $ 53 264,503 (7,146) (166) (172,183) 85,061
Ending balance (in shares) at Apr. 03, 2021 50,603          
Increase (Decrease) in Stockholders' Equity            
Net income (loss)         2,072 2,072
Issuance of shares in connection with stock option exercise $ 2 2,615       2,617
Issuance of shares in connection with stock option exercise (in shares) 1,463          
Share-based compensation   3,821       3,821
Issuance of shares in connection with BOD Fees   6       6
Issuance of stock awards   389       389
Issuance of stock awards (in shares) 118          
Unrealized gain (loss) on deferred compensation trust assets       38   38
Effect of changes in foreign currencies       16   16
Ending balance at Jul. 03, 2021 $ 55 271,334 (7,146) (112) (170,111) 94,020
Ending balance (in shares) at Jul. 03, 2021 52,184          
Increase (Decrease) in Stockholders' Equity            
Net income (loss)         (4,659) (4,659)
Issuance of shares in connection with stock option exercise   451       451
Issuance of shares in connection with stock option exercise (in shares) 108          
Issuance of shares in connection with restricted stock units vesting (in shares) 109          
Share-based compensation   4,364       4,364
Issuance of shares in connection with BOD Fees   6       6
Issuance of stock awards   233       233
Issuance of stock awards (in shares) 14          
Unrealized gain (loss) on deferred compensation trust assets       (5)   (5)
Effect of changes in foreign currencies       60   60
Ending balance at Oct. 02, 2021 $ 55 276,388 (7,146) (57) (174,770) 94,470
Ending balance (in shares) at Oct. 02, 2021 52,415          
Beginning balance at Jan. 01, 2022 $ 56 282,663 (7,625) 274 (179,800) 95,568
Beginning balance (in shares) at Jan. 01, 2022 52,960          
Increase (Decrease) in Stockholders' Equity            
Net income (loss)         2,103 2,103
Issuance of shares in connection with stock option exercise   792       792
Issuance of shares in connection with stock option exercise (in shares) 533          
Issuance of shares in connection with restricted stock units vesting $ 1 (1)        
Issuance of shares in connection with restricted stock units vesting (in shares) 519          
Issuance of stock awards to consultants   81       81
Issuance of stock awards to consultants (in shares) 10          
Share-based compensation   4,225       4,225
Issuance of shares in connection with BOD Fees   6       6
Issuance of shares in connection with ESPP   431       431
Issuance of shares in connection with ESPP (in shares) 45          
Officers and directors stock purchase plan   23       23
Officers and directors stock purchase plan (in shares) 3          
Unrealized gain (loss) on deferred compensation trust assets       (34)   (34)
Effect of changes in foreign currencies       20   20
Ending balance at Apr. 02, 2022 $ 57 288,220 (7,625) 260 (177,697) 103,215
Ending balance (in shares) at Apr. 02, 2022 54,070          
Beginning balance at Jan. 01, 2022 $ 56 282,663 (7,625) 274 (179,800) $ 95,568
Beginning balance (in shares) at Jan. 01, 2022 52,960          
Increase (Decrease) in Stockholders' Equity            
Issuance of shares in connection with stock option exercise (in shares)           665
Ending balance at Oct. 01, 2022 $ 57 293,450 (7,625) 228 (174,527) $ 111,583
Ending balance (in shares) at Oct. 01, 2022 54,558          
Beginning balance at Apr. 02, 2022 $ 57 288,220 (7,625) 260 (177,697) 103,215
Beginning balance (in shares) at Apr. 02, 2022 54,070          
Increase (Decrease) in Stockholders' Equity            
Net income (loss)         4,118 4,118
Issuance of shares in connection with stock option exercise   136       136
Issuance of shares in connection with stock option exercise (in shares) 70          
Issuance of shares in connection with restricted stock units vesting (in shares) 220          
Share-based compensation   771       771
Issuance of shares in connection with BOD Fees   6       6
Officers and directors stock purchase plan   4       4
Unrealized gain (loss) on deferred compensation trust assets       (100)   (100)
Effect of changes in foreign currencies       104   104
Ending balance at Jul. 02, 2022 $ 57 289,137 (7,625) 264 (173,579) 108,254
Ending balance (in shares) at Jul. 02, 2022 54,360          
Increase (Decrease) in Stockholders' Equity            
Net income (loss)         (948) (948)
Issuance of shares in connection with stock option exercise   184       184
Issuance of shares in connection with stock option exercise (in shares) 63          
Issuance of shares in connection with restricted stock units vesting (in shares) 72          
Share-based compensation   3,760       3,760
Issuance of shares in connection with BOD Fees   6       6
Issuance of shares in connection with BOD Fees (in shares) 1          
Issuance of shares in connection with ESPP   363       363
Issuance of shares in connection with ESPP (in shares) 62          
Unrealized gain (loss) on deferred compensation trust assets       (36)   (36)
Ending balance at Oct. 01, 2022 $ 57 $ 293,450 $ (7,625) $ 228 $ (174,527) $ 111,583
Ending balance (in shares) at Oct. 01, 2022 54,558